<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               INDICATIONSÂ AND USAGE<BR>               <BR>                  TRISENOX is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.<BR>                  The response rate of other acute myelogenous leukemia subtypes to TRISENOX has not been examined.<BR>               <BR>               <BR>            <BR>         </P></DIV></HTML>